Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies

被引：21
作者：
Cao, Hanyu [1 ]
You, Di [1 ]
Lan, Zhu [2 ]
Ye, Hui [1 ]
Hou, Minmin [1 ,3 ]
Xi, Mingrong [1 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Gynecol & Obstet, 20 Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol China, Terahertz Sci & Technol Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2018年 / 18卷 / 04期
基金：
美国国家科学基金会;
关键词：
Human epididymis protein 4; ovarian cancer; prognosis; survival; recurrence; EPIDIDYMIS PROTEIN 4; PREDICT OPTIMAL CYTOREDUCTION; NEWCASTLE-OTTAWA SCALE; DIAGNOSTIC PERFORMANCE; MALIGNANCY ALGORITHM; ROMA ALGORITHM; CA125; BIOMARKER; CHEMOTHERAPY; CA-125;
D O I：
10.1080/14737159.2018.1457436
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Introduction: Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. Accumulating evidence showed an evolving role of HE4 in monitoring the progression and prognosis of OC but without a comprehensive analysis for prognosis and survival data.Areas covered: The present meta-analysis aims to explore the association of HE4 with survival and the clinicopathological features of OC patients. PubMed, Embase, Web of Science and the China National Knowledge Infrastructure (CNKI) were searched for relevant studies regarding the role of both serum and tissue HE4 expression in ovarian cancer.Expert commentary: HE4 has been proposed as the most promising biomarker that may complement the CA125 expression and has been approved by the FDA in monitoring the follow-up and relapse of OC patients. Our results are in accordance with the most recent evidence suggesting its important role in the prognostic surveillance of OC and a better performance in the early prediction of OC recurrence than CA125.
引用
收藏
页码：371 / 383
页数：13
相关论文
共 123 条
[91]  
Wang YC, 2012, MOD ONCOL, V4, P785
[92]  
Wang YK, 2015, MED RECAPITULATE, V21, P1700
[93]  
Wang ZQ, 2014, PRACT J CANC, V4, P412
[94]  
Wu HJ, 2015, CHINA MED PHARM, V5, P123
[95]  
Wu XM, 2014, J NANCHANG U MED SCI, V54, P51
[96]  
Xie YM, 2014, MED J W CHINA, V26, P576
[97]  
Xu FL, 2013, CHIN J CLINICIANS, V7, P2407
[98]  
Xu K, 2015, CHIN J CLIN OBSTET G, V30, P3725
[99]  
Xu LJ, 2016, J HAINAN MED U, V22, P503
[100]   Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China [J].
Xu, Ying ;
Zhong, Rihui ;
He, Jian ;
Ding, Rui ;
Lin, Haixiong ;
Deng, Yawen ;
Zhou, Lijun ;
Li, Xiaohui ;
Jiang, Junyi ;
Bao, Yunwen ;
Luo, Xiaohong ;
Duan, Chaohui .
CLINICAL BIOCHEMISTRY, 2016, 49 (1-2) :32-40
45678910111213